anti-PD-(L)1 inhibitors
7 abstracts
Abstract
Fecal microbiota transplantation combined with anti-PD-(L)1 inhibitors as first-line maintenance therapy for advanced gastric and non small cell lung cancer.Org: The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, The Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, China, Changzhou Second People’s Hospital, Changzhou, China,
Abstract
Immune checkpoint inhibitor (ICI) rechallenge after immune-related adverse events (irAE) requiring hospitalization: A single-center 10-year experience.Org: Far Eastern Memorial Hospital, Salem,
Abstract
Efficacy and clinicogenomic biomarkers of response to dual versus single agent checkpoint inhibitor therapy in untreated metastatic non-small cell lung cancer.Org: Department of Medicine, Tufts Medical Center, Boston, MA, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, Lowe Center for Thoracic Oncology, Boston, MA, Centre de Recherche Du Centre Hospitalier de L'Université de Montréal, Montreal, QC, Canada, Dana-Farber Cancer Center, Boston, MA,
Abstract
Immuno-related cardiac toxicity in patients with cancer: A prospective study applying multiparametric cardiac MRI.Org: Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy, Cardiology Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milano), Italy, Biostatistic Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy, Adaptive Immunity Laboratory, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy,
Abstract
Association between physical activity, immune-related adverse events, and mortality in patients undergoing immune checkpoint inhibition.Org: University Medical Center Utrecht,
Abstract
Fecal microbiota transplantation combined with anti-PD-1 inhibitor for unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor.Org: Gwangju Institute of Science and Technology (GIST), prismCDX Co., Ltd, Asan Institute for Life Sciences, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,
Abstract
Clinical and molecular features of long-term response to anti-PD-(L)1 therapy in patients with advanced non-small cell lung cancer.Org: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Clinical Oncology Center, Polytechnic University of Marche,